SignalFDA/Bio
Elicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer Transcript
Elicio discusses Camupepimut development in neoadjuvant and metastatic pancreatic cancer.
Context
What happened: Elicio Therapeutics (ELTX) held a virtual KOL event discussing camupepimut development in neoadjuvant and metastatic KRAS-mutated pancreatic ductal adenocarcinoma. Speakers included Dr. Kevin Soares of Memorial Sloan Kettering, principal investigator of the neoadjuvant Phase 1 study, and Dr. Eileen O'Reilly.
Key numbers: Event dated November 11, 2026, 2:30 PM EST.
Why it matters: The call addressed investor questions about the recent start-up of the neoadjuvant Phase 1 study of camupepimut.
What changed
Elicio Therapeutics (ELTX) held a virtual KOL event discussing camupepimut development in neoadjuvant and metastatic KRAS-mutated pancreatic ductal adenocarcinoma. Speakers included Dr. Kevin Soares of Memorial Sloan Kettering, principal investigator of the neoadjuvant Phase 1 study, and Dr. Eileen O'Reilly.
Why it matters
The call addressed investor questions about the recent start-up of the neoadjuvant Phase 1 study of camupepimut.